i
Evidence to Recommendation Framework : Moderna COVID-19 vaccine in children ages 6 – 11 years and adolescents ages 12 – 17 years
-
June 23, 2022
Series: ACIP meeting COVID-19 Vaccines
Select the Download button to view the document
This document is over 5mb in size and cannot be previewed
Details:
-
Personal Author:
-
Corporate Authors:
-
Conference Authors:
-
Subject:
-
Series:
-
Document Type:
-
Name as Subject:
-
Genre:
-
Collection(s):
-
Main Document Checksum:urn:sha256:a92d37f313679b02d7b4d305ced2d747ce91b0564d1afd888f4a29bf39e530e2
-
File Type:
Supporting Files
-
No Additional Files
More +
Related Documents
-
- File Format:
- RIS
- File Format:
- RIS
- File Format:
- RIS
Economic analysis and public health impact of PCV15 use among children in the USCiteEpidemiology and burden of respiratory syncytial virus in older adults in the U.S.CiteInterim clinical considerations update : Moderna COVID-19 vaccine for children ages 6−17Cite
More +
You May Also Like
Checkout today's featured content at stacks.cdc.gov